Grant: Canada Postdoctoral Research Award (CPRA) program
Direct Payment
$140,000.00
Leveraging genetic vulnerabilities to identify new antibiotic targets in Pseudomonas aeruginosa
EF 2025-26
Résumé
The world is currently facing a silent pandemic of antimicrobial resistance. It is estimated that antimicrobial resistant infections will claim the lives of ten million people each year by the year 2050. Healthcare practitioners will soon have few options available due to the stalled pace of new antibiotic development. We believe the difficulty with developing antibiotics is a knowledge gap in the fundamental biology of bacteria. Despite the progress made during the genomic era of biology, where bacterial genomes can be completely sequenced, identifying the most vulnerable genes and their functions within the cell has been incredibly challenging. This makes it difficult to find new targets for antibiotic development. However, this is now becoming possible with the development of new genomic technologies. We propose that the most vulnerable genes, which have profound impacts on the growth of the bacteria when perturbed, will be promising new antibiotic targets. We have already created the tools to disrupt genes in bacteria as well as to capture a snapshot of their biological functions. Thus, we are poised to begin identifying the most vulnerable genes in bacteria and their associated functions. We believe this work will provide the missing piece of gene vulnerabilities, which can catalyze new biological insights and spark increased efforts towards the next generation of antibiotics.
Programme
Canada Postdoctoral Research Award (CPRA) program
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
537070
Name
Sullivan Jaryd R
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Leveraging genetic vulnerabilities to identify new antibiotic targets in Pseudomonas aeruginosa
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Crispr-Interference; Drug Discovery; Drug Targets; Gene Vulnerabilities; Genetic Perturbations; Perturb-Seq; Pseudomonas Aeruginosa; Scrna-Seq
Abstract
The world is currently facing a silent pandemic of antimicrobial resistance. It is estimated that antimicrobial resistant infections will claim the lives of ten million people each year by the year 2050. Healthcare practitioners will soon have few options available due to the stalled pace of new antibiotic development. We believe the difficulty with developing antibiotics is a knowledge gap in the fundamental biology of bacteria. Despite the progress made during the genomic era of biology, where bacterial genomes can be completely sequenced, identifying the most vulnerable genes and their functions within the cell has been incredibly challenging. This makes it difficult to find new targets for antibiotic development. However, this is now becoming possible with the development of new genomic technologies. We propose that the most vulnerable genes, which have profound impacts on the growth of the bacteria when perturbed, will be promising new antibiotic targets. We have already created the tools to disrupt genes in bacteria as well as to capture a snapshot of their biological functions. Thus, we are poised to begin identifying the most vulnerable genes in bacteria and their associated functions. We believe this work will provide the missing piece of gene vulnerabilities, which can catalyze new biological insights and spark increased efforts towards the next generation of antibiotics.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Sullivan, Jaryd R
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~